Genital Warts - Pipeline Insight, 2024

Genital Warts - Pipeline Insight, 2024

DelveInsight’s, “Genital Warts – Pipeline Insight, 2024,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Genital Warts Understanding

Genital Warts: Overview

Genital warts are the most common viral sexually transmitted infection (STI). They’re caused by the human papilloma virus (HPV) which can be passed on during sexual contact. Not everyone who has the virus develops genital warts. For most people, including those who have visible warts, the virus will be cleared from the body over time. It’s rare for genital warts to cause any long-term health problems.

Symptoms

Symptoms include:

• One or more small, flesh-coloured or grey painless growths or lumps around your vagina, penis, anus or upper thighs
• Itching or bleeding from your genitals or anus
• A change to your normal flow of pee (for example, sideways), that doesn't go away.

Diagnosis

The main check for genital warts is for a doctor or nurse to look at the warts. They may do this using a magnifying lens. The patient may also need an internal examination of the vagina or the anus to see if there are any warts inside. Rarely, it may be necessary to take a biopsy (small sample) of the wart for closer examination. Depending on the area being examined, a local anaesthetic may be used.

Treatment

The sooner genital warts are treated, the easier they are to get rid of. There are two main types of treatment for genital warts. The type of treatment you receive will depend on the type of warts you have and where the warts are. Treatments include:

• Applying a cream, lotion or chemicals to the warts
• Destroying the warts by freezing, heating or removing them.

Genital Warts Emerging Drugs Chapters

This segment of the Genital Warts report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Genital Warts Emerging Drugs

• VP-102: Verrica Pharmaceuticals

Verricaʼs lead product candidate, VP-102, is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin (0.7% w/v) delivered via a single-use applicator that allows for precise topical dosing and targeted administration. Verrica is developing VP-102 for the treatment of molluscum contagiosum (molluscum), common warts and external genital warts, three of the most common viral skin diseases in medical dermatology.

• SB206: Novan

Novan is developing SB206 as a topical antiviral gel for the treatment of viral skin infections, including external genital warts (EGW) caused by human papillomavirus (HPV). SB206 exhibited a dose responsive pharmacologic effect with complete inhibition of papilloma growth compared to topical imiquimod in an in vivo model. NVN1000, the active pharmaceutical ingredient in SB206, exhibited a dose dependent decrease in HPV viral replication in human raft cell culture model.

• CB-06-02: Cassiopea

CB-06-02, a NCE, immune modulator is being developed for the treatment of genital warts. Cassiopea believes it is the first potential treatment for this condition based on tellurium, a rare element. It acts as a low-toxicity immunomodulator in supporting the natural immune response against Human Papilloma Virus, or HPV. Based on the drug profiling Cassiopea has performed to date, the Company believes CB-06-02 has the potential to have a faster onset of action and a lower recurrence rate than currently available treatments.

Further product details are provided in the report……..

Genital Warts: Therapeutic Assessment

This segment of the report provides insights about the different Genital Warts drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Genital Warts

There are approx. 30+ key companies which are developing the therapies for Genital Warts. The companies which have their Genital Warts drug candidates in the most advanced stage, i.e. phase II include Verrica Pharmaceuticals and others

• Phases

DelveInsight’s report covers around 30+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Genital Warts pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravenius
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Gene therapies
• Small molecule
• Vaccines
• Polymers
• Peptides
• Monoclonal antibodies
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Genital Warts: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II I, preclinical and discovery stage. It also analyses Genital Warts therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Genital Warts drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Genital Warts R&D. The therapies under development are focused on novel approaches to treat/improve Genital Warts.
• In July 2018, Cassiopea announced that the proof of concept phase II clinical trial for its CB-06-02 topical 15% immune modulator tellurium-based gel for the treatment of external genital warts in women demonstrated statistically significant successful complete clearance rates in the PP population and successful complete clearance rates in the ITT population.

Genital Warts Report Insights

• Genital Warts Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Genital Warts Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Genital Warts drugs?
• How many Genital Warts drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Genital Warts?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Genital Warts therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Genital Warts and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• ViroXis Corporation
• bioRASI, LLC
• Verrica Pharmaceuticals Inc.
• Orgenesis
• Heber Biotec
• Cassiopea
• Novan
• Peritech Pharma
• Novartis

Key Products

• VIR007
• Ranpirnase
• CIGB 300
• AS 101
• VP-102
• SB206
• PP 210
• LFX 453